All In Biotech

Drug Trial Radar · NCT05135559

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Mar 24, 2022

Primary completion

Apr 21, 2026

Study completion Nov 2, 2029

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.

Conditions

  • Haemophilia A and B With and Without Inhibitors

Interventions

  • ConcizumabDrug

    Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodesTime frame: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
  2. For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodesTime frame: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Locations

91 sites in 24 countries. Site status is shown where the registry gives one.

  • Rady Childrens Hosp San Diego

    San Diego, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Arnold Palmer Children's Hospital

    Orlando, Florida

  • Nemours Child Orlando Hem/Onc.

    Orlando, Florida

  • Augusta Univ/Childrens Hosp-GA

    Augusta, Georgia

  • Memorial Health University Medical Center

    Savannah, Georgia

  • Childrens Hospital of Chicago

    Chicago, Illinois

  • Indiana Hemophilia-Thromb Ctr

    Indianapolis, Indiana

  • Children's Hosp-New Orleans

    New Orleans, Louisiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • The Children's Mercy Hospital

    Kansas City, Missouri

  • Children's Nebraska

    Omaha, Nebraska

  • ECU Sickle Cell Comp Clinic

    Greenville, North Carolina

  • Nationwide Children's Hospital

    Columbus, Ohio

  • St Christopher Hosp for Child

    Philadelphia, Pennsylvania

  • Monroe Carell Jr. Children's Hospital at Vanderbilt

    Nashville, Tennessee

  • Cook Children's Hospital-Hematology-Oncology

    Fort Worth, Texas

  • Texas Children's Hospital_Houston

    Houston, Texas

  • Pediatrics Hematology/Oncology Clinic Battle Building

    Charlottesville, Virginia

  • Haematology and Blood Bank Department

    Algiers, Algeria

  • CHU Constantine BEN BADIS/ Hematology department

    Constantine, Algeria

  • University Clinical Center of Republic Srpska (545)

    Banja Luka, Bosnia and Herzegovina

  • University Clinical Centre Tuzla

    Tuzla, Bosnia and Herzegovina

  • UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics

    Plovdiv, Bulgaria

  • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology

    Sofia, Bulgaria

  • UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology

    Varna, Bulgaria

  • BC Children's Hospital

    Vancouver, British Columbia, Canada

  • McMaster Children's Hospital

    Hamilton, Ontario, Canada

  • Tallinn Children's Hospital

    Tallinn, Estonia

  • Centre Hospitalier Metropole Savoie

    Chambéry, France

  • Ap-Hp-Hopital de Bicetre-1

    Le Kremlin-Bicêtre, France

  • AP-HP-HOPITAL NECKER_Service d'hématologie

    Paris, France

  • Aghia Sophia Childrens' Hospital

    Athens, Greece

  • 'Ippokrateio' General Hospital of Thessaloniki

    Thessaloniki, Greece

  • 'Ippokrateio' General Hospital of Thessaloniki

    Thessaloniki, Greece

  • Guwahati Medical College

    Guwahati, Assam, India

  • Nirmal Hospital Pvt. Ltd.

    Surat, Gujarat, India

  • SSSH_Dept. of Clinical Haematology & Haemato Oncology

    Kolhāpur, Maharashtra, India

  • Seth GS Medical College & KEM Hospital

    Mumbai, Maharashtra, India

  • K.J Somaiya Hospital and Research Centre

    Mumbai, Maharashtra, India

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.